Guidelines

Various reviews, guidelines and recommendation papers are produced under the EMN umbrella. To collect & better coordinate the various proposals and manuscripts, a guideline team is in place: Monika Engelhardt from Germany, Niels van de Donk from the Netherlands, Francesca Gay from Italy and Evangelos Terpos from Greece.

 

Review articles

  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project view
  • COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network view
  • 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde view
  • Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) view
  • Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network view
  • Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. view
  • Management of Patients With Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper From the European Myeloma Network (EMN) view
  • Time From First Symptom Onset to the Final Diagnosis of Multiple Myeloma (MM) – Possible Risks and Future Solutions: Retrospective and Prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) Analysis view
  • Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma: A Consensus Statement From The European Myeloma Network view
  • Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. view
  • Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. view
  • Insights on Multiple Myeloma Treatment Strategies view
  • European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when view
  • Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) view
  • European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias view
  • From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives view
  • Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network view
  • Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network view
  • Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) view
  • Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) view
  • Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders view
  • Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) view
  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma view
  • The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network view
  • Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network view
  • European Myeloma Network guidelines for the management of multiple myeloma-related complications view
  • European myeloma network: the value of collaborative research view
  • Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders view
  • The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network view
  • A new co-operative group: the European Myeloma Network Trialist Group view
  • European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. view
  • Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement view
  • Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. view
  • Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. view
  • Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). view